Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
6.92
+0.17 (2.52%)
Apr 8, 2026, 11:23 AM EDT - Market open
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,375,598
Market Cap
725.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -3 | -15.00% |
| Dec 31, 2023 | 20 | 6 | 42.86% |
| Dec 31, 2022 | 14 | 4 | 40.00% |
| Dec 31, 2021 | 10 | -4 | -28.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Maravai LifeSciences Holdings | 435 |
| Arvinas | 246 |
| Solid Biosciences | 121 |
| BridgeBio Oncology Therapeutics | 92 |
| Lexicon Pharmaceuticals | 81 |
| Alto Neuroscience | 68 |
| Design Therapeutics | 54 |
RLMD News
- 19 days ago - Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update - GlobeNewsWire
- 27 days ago - Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 - GlobeNewsWire
- 4 weeks ago - Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing - GlobeNewsWire
- 4 weeks ago - Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 3 months ago - Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - GlobeNewsWire
- 4 months ago - Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewsWire
- 5 months ago - Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates - GlobeNewsWire